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Abstract 
Introduction: 
Testicular seminomas require accurate staging for effective management. 20% are metastatic at 
presentation while 80% are clinical stage I, requiring only orchiectomy and surveillance.  Tumor size, 
rete testis invasion, hilar soft tissue invasion, and lymphovascular invasion have been shown to incur 
a higher risk of metastasis and recurrence in clinical stage I seminomas, with little congruence 
between studies.    
 
Materials and Methods: 
We reviewed 211 cases of testicular seminomas and recorded patient age, tumor size, 
lymphovascular invasion and rete testis, hilar soft tissue, epididymis, spermatic cord, tunica 
albuginea, and tunica vaginalis involvement. A univariate and multivariate analysis was performed 
comparing clinical stage I to advanced clinical stage patients (stages II and III) in reference to these 
factors.  
 
Results: 
We found that tumor size (p=0.02), vascular invasion (p=0.02), and invasion of rete testis stroma 
(p=0.01), epididymis (p=0.02), spermatic cord (p=0.047), and hilar soft tissue (p=0.04) were 
predictors of higher clinical stage at the univariate level. However, multivariate analysis showed that 
only tumor size and vascular invasion remained significant (p=0.008 and 0.032, respectively).  A 
tumor size of 4 cm was the size cutoff found to be significant.  
 
Discussion: 
Tumor size and vascular invasion are the strongest predictors of higher clinical stage in testicular 
seminomas.  Our univariate data suggests that rete testis and hilar soft tissue invasion relate to 
higher clinical stage.  However, neither of these factors were found to be independent risk factors at 
multivariate analysis. Therefore, this study supports tumor upstaging based only upon size and 
vascular invasion. 
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Introduction 
Testicular germ cell tumors are the most common solid organ malignancy in males 20-35 
years old, with pure testicular seminomas representing up to 60%.1  Seminomas are highly treatable, 
with 80% of patients presenting at low stage disease (clinical stage I) and managed with orchiectomy 
and imaging surveillance.2  However, many large studies have now shown that the relapse rate of 
clinical stage I seminoma treated by orchiectomy and surveillance alone is between 15 and 20%.  
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Most of these cases recur within 12-18 months and many are theorized to have occult metastases at 
the time of presentation.3  Therefore, identifying risk factors for metastatic disease (or advanced 
clinical stage) is important to understand which patients are at a higher risk of subclinical metastases 
at presentation and, therefore, recurrence. 
Previous studies have attempted to develop models for risk of recurrence in clinical stage I 
seminomas.  The results of these studies have been inconsistent, with tumor size as the only 
consistent predictor of increased recurrence but with difference in size cutoffs.  Other purported 
predictors including lymphovascular invasion, rete testis invasion, and hilar soft tissue invasion have 
had variable support.4-9  Kollmannsberger et al. demonstrated that advanced disease was seen with 
both early and late relapse patients, and did not see a correlation between current IGCCC risk 
stratification criteria and likelihood of relapse as all of their relapsed seminoma cases were good risk 
disease.  Thus, further characterization of risk factors for recurrence, such as degree of locally 
advanced disease at the time of diagnosis, is needed.10 Therefore, we wished to undertake a 
comprehensive analysis of possible prognostic factors in seminomas and their relationship to 
metastasis at the time of presentation, particularly in light of recent changes to the pathologic 
staging of testicular germ cell tumors in the American Joint Committee on Cancer staging manual (8th 
edition).11  
Methods 
We retrospectively collected 211 consecutive in-house cases (2000-2016) of pure testicular 
seminomas and reviewed the microscopic slides, pathology reports, and clinical histories.  The final 
cohort consisted of 170 cases, as clinical stage was not available in 41 cases.  The microscopic slides 
were reviewed by three pathologists prior to the collection of clinical stage data.  Patient age, tumor 
size, lymphovascular invasion (LVI) and rete testis, hilar soft tissue, epididymis, spermatic cord, 
tunica albuginea, and tunica vaginalis involvement were recorded. Direct rete testis and epididymal 
invasion versus pagetoid spread was specifically recorded.  Rete testis tumor invasion was defined as 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
tumor cells in the stroma on both sides of a tubular channel or clear destruction of the testicular 
hilum (figure 1), and hilar soft tissue invasion was defined as tumor extension into the soft tissue 
beyond the rete testis at the same plane of section as the testis parenchyma (figure 2).  Spermatic 
cord invasion was defined as tumor grossly extending beyond the hilum, with the base defined as 
the section just superior to the head of the epididymis.  Lymphovascular invasion was defined as 
cohesive cells, adherent to the wall of the blood vessel, preferably located in a peritumoral or tunica 
albuginea location.  Associated fibrin material further supports the presence of lymphovascular 
invasion.  Tunica albuginea invasion was defined as invasion into the fibrous layer immediately 
surrounding the testicular parenchyma.  Tunica vaginalis invasion was defined as invasion into or 
through the mesothelial layer surrounding the tunica albuginea. These definitions were composed 
by a combination of recent suggestions in the AJCC 8th edition guidelines for testis staging, Verrill et 
al.’s recommendations in the recent International Society of Urological Pathology (ISUP) guidelines 
on reporting and staging of testicular germ cell tumors, and the combined experience of multiple 
specialist genitourinary pathologists at our institution in situations where the two previously 
mentioned sources are not entirely clear.11,12  
Clinical stage was assessed from medical records at the time of presentation.  Abdominal 
and pelvis CT and chest X-ray were available for all 170 patients included in the cohort.  Additional 
evidence of metastasis and serum tumor markers were additionally noted when determining the 
clinical stage.  Cases were then sub-classified as either clinical stage I (including IA, IB, and IS stages) 
or advanced clinical stage (stage II and above).   
  Binary categorical variables (lymphovascular, rete testis, hilar soft tissue, epididymis, 
spermatic cord, tunica albuginea, and tunica vaginalis invasion) were collected and frequency and 
proportions were recorded for clinical stage I and advanced clinical stage groups.  Continuous 
variables (age and tumor size) were kept in whole years for age and rounded to the nearest 1 mm 
for tumor size.  Means were calculated for both age and tumor size in the clinical stage I and 
advanced clinical stage groups.  On gross report and slide review, only tumor size, vascular invasion, 
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spermatic cord invasion, and tunica vaginalis invasion could be evaluated on every case included.  A 
number of cases did not have adequate sampling of the testicular hilum and epididymis due to the 
year range that was included in the cohort.  Therefore, each incomplete category had frequencies 
counted and proportions were calculated based on the number of cases that were evaluable for that 
particular variable.  Additionally, frequencies were calculated for the number of cases less than and 
greater than 2cm, 3cm, and 4cm in both the clinical stage I and advanced clinical stage groups. 
A univariate and multivariate analysis was performed comparing clinical stage I to higher 
clinical stage patients (stage II and III) in reference to these factors.  Univariate analysis was 
performed using Fisher’s exact test for binary variables and the two sample t-test for continuous 
variables.  Additionally, chi square testing was used to evaluate tumor size data with the various 
cutoffs recorded (2 cm, 3 cm, and 4 cm).  Logistical regression was performed for multivariate 
analysis with forward stepwise selection of variables.  The odds ratio was calculated for all 
statistically significant variables at the multivariate level.  The final logistical regression model was 
used to form a receiver operating curve to evaluate the performance of the statistically significant 
variables at predicting higher clinical stage.  A p-value of <0.05 was set as statistically significant for 
all tests.  All statistics were performed using Excel and SAS programs (Microsoft Office 2016, SAS 
Institute 2013).  
 
Results 
Clinical findings 
Of the 170 cases included in the cohort, 138 (81%) were clinical stage I and 32 (19%) were advanced 
clinical stage (stages II and III).  The mean patient age was 37 years (range 19-68 years).  (Table 1) 
Pathologic findings 
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Of the 170 cases, the mean tumor size was 4.2 cm (range of 0.4-11.5 cm). Lymphovascular invasion 
was demonstrated in 25 cases (15%), spermatic cord invasion in 5 (3%), and tunica vaginalis 
involvement in 4 (2%).  Rete testis invasion was identified in 90/155 (58%) cases whereas pagetoid 
spread was seen in 28/145 (19%).  Invasion of hilar soft tissue occurred in 34/158 (22%), epididymis 
in 9/162 cases (6%) (with pagetoid spread in 1/160 [<1%]), and tunica albuginea in 48/148 (32%). 
(Figure 1A-D) None of the cases had revised diagnoses (all remained pure seminoma) or revised 
clinical staging on re-review of the pathologic and clinical data.  As pathologic staging was irrelevant 
to the analysis of each binary and continuous variable individually, this data was unaffected by the 
AJCC 8th edition update to testicular cancer staging.  All cases were unilateral, with 211 separately 
represented patients. 
 The clinical and pathologic findings in clinical stage I cases versus those of advanced clinical 
stage are shown in Table 1.  On univariate analysis, tumor size, vascular invasion, spermatic cord 
invasion, and epididymal invasion were significantly more common in cases of advanced clinical 
stage than in stage I disease (Table 1).  Additionally, on univariate analysis, age, rete testis invasion, 
rete testis pagetoid spread, hilar soft tissue invasion, epididymal pagetoid spread, tunica vaginalis 
involvement, and tunica albuginea involvement were not significantly different between cases of 
clinical stage I and advanced clinical stage.  
 On multivariate analysis, only tumor size and vascular invasion were significant independent 
predictors of higher clinical stage (Table 2).  A logistical regression model was created using these 
two variables and is represented in a receiver operating curve with an area under the curve of 0.7 
(figure 2). 
 Additionally, the various cutoffs trialed for tumor size showed significantly higher risk of 
metastatic disease only with use of the 4 cm cutoff (Table 3).  There was no statistical difference in 
the rate of advanced clinical stage when using both 2 cm and 3 cm cutoffs. 
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Discussion 
 This study identified tumor size and vascular invasion as strong predictors of advanced 
clinical stage and thus metastases at presentation in pure testicular seminomas.  Additionally, we 
found the most appropriate cutoff point for upstaging based on tumor size to be <4 cm versus >/=4 
cm based on the increased likelihood of metastases in tumors >/=4 cm.  This was not true of the 
smaller cutoff values, 2 cm and 3 cm respectively.  These findings differ from those previously 
described in nonseminomatous germ cell tumors in the lack of support for hilar soft tissue, 
epididymal invasion, and rete testis invasion as prognostic risk factors, as well as the recently revised 
American Joint Committee on Cancer staging of germ cell tumors, which includes hilar soft tissue 
and epididymal invasion and a size cut off of 3 cm.11,13   
 Previous studies on risk factors for recurrence in pure seminomas have identified tumor size, 
vascular invasion, rete testis invasion, and increased age as predictors of recurrence or metastasis at 
presentation.  However, many studies have found different and conflicting factors as significant, with 
validation in different institutions proving to be difficult.   The largest of these studies demonstrated 
tumor size and rete testis invasion to be significant risk factors for recurrence in clinical stage I 
seminomas.9  However, this study utilized pooled data from 4 different centers and historical data 
from pre-existing pathology reports without re-review of historic slides, unlike our study.  
Furthermore, external validation of this study by Chung et al.4 identified only tumor size to be an 
independent risk factor at multivariate analysis, which was additionally supported by Vogt et al. who 
found rete testis involvement not to be a significant risk factor in a combined seminoma and 
nonseminoma cohort.4,7 The significance of tumor size was reconfirmed in a follow up study by 
Nayan et al. which described significant differences in relapse rates of seminomas based on tumor 
size.14  
Other studies have found lymphovascular invasion and age to be significant risk factors, but 
these findings have not been confirmed in other institutions.5,8  As Lymphovascular invasion is a well-
supported prognostic factor in nonseminomatous germ cell tumors, the recent ISUP publication on 
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reporting and staging testicular germ cell tumors specifically calls for further studies to provide high 
level evidence of lymphovascular invasion in pure seminomas.10 12Thus, our study helps to fill this 
need by providing clear evidence of multivariate significance of lymphovascular invasion in pure 
seminomas specifically. 
 Unlike the recent study on nonseminomatous germ cell tumors by Yilmaz et al10, our study 
did not find hilar soft tissue invasion and rete testis invasion to be independent predictors of 
advanced clinical stage in pure seminomas.  However, our study did concur with Yilmaz et al that 
vascular invasion is an independent risk factor.  This lack of congruence between support for these 
risk factors (in particular hilar soft tissue and rete testis invasion) in seminomas and nonseminomas 
could be due to the aggressive nature of nonseminomas in comparison to pure seminomas, and this 
fact is not adequately addressed by the current AJCC staging system which cites evidence for 
upstaging based on hilar soft tissue and epididymal invasion based on studies done on only 
nonseminomas.11 
 Although our results did not support other histologic and clinical criteria as independent risk 
factors for metastases outside of tumor size and vascular invasion, there were limits to our study.  As 
testicular germ cell tumors are fairly uncommon tumors, the number of cases available to study was 
low and impact the power of the study.  In particular, the number of cases with advanced clinical 
stage (N=32) in cases of pure seminoma were limited.  In comparison to studies of non-seminomas 
in which presentation at a higher clinical stage is more likely, a large cohort of advanced clinical 
stage patients is unavailable.  Similarly, our ability to analyze the impact of factors associated with 
local growth (advanced pathologic T-stage) was limited by few cases showing aggressive local 
invasion because of the relatively indolent tendencies of many seminomas.  Hence, we found only 5 
cases with spermatic cord invasion, 1 with epididymal pagetoid spread, 9 with epididymal invasion, 
and 4 with tunica vaginalis invasion.  The remaining criteria evaluated had a larger number of 
positive cases (N>/=25). 
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Additionally, our multivariate analysis was impacted by missing data.  Of the criteria studied, 
only vascular invasion, tumor size, age, and spermatic cord invasion were available in all cases, while 
a number of the other cases were missing one or more of the studied criteria (Table 1).  This led to 
cases being eliminated from consideration in the logistical regression.  Likewise, a number of the 
criteria examined demonstrated a great deal of overlap; rete testis and hilar soft tissue for example, 
which made proving independence difficult.  Thus, hilar invasion may be more easily proven 
significant by grouping all hilar invasion (rete testis, hilar soft tissue, and epididymis invasion) into 
one category in future studies.  While this would not allow for elucidation of each factor individually, 
it would allow for clarification of the impact of hilar invasion in pure seminomas, which other studies 
have also struggled to validate.4  
Our study was additionally limited by the use of advanced clinical stage at presentation as a 
proxy for increased risk of relapse.  The use of advanced clinical stage at diagnosis as an alternative 
to direct recurrence data as a prognostic indicator was performed in a cohort of nonseminomas by 
Yilmaz et al previously, and this paper is regarded as strong evidence in the recent AJCC 8th edition 
update.11,13 Advanced stage disease was additionally chosen over relapse data directly due to the 
confounded nature of current relapse data due to differences in treatment among those with clinical 
stage I disease over the time period tested.  While there is much support to the use of surveillance in 
all of these patients, the clinical scenario including the degree of locally advanced disease, the 
likelihood of patient compliance, and patient anxiety, all influence the decision of whether to use 
adjuvant chemotherapy or radiation at the time of orchiectomy.15   Additionally, our institution is a 
tertiary care center that provides orchiectomy and care planning for a large surrounding area.  Thus, 
a number of patients chose to undergo surveillance closer to home once their original care plan is in 
place, making this data unavailable to us currently.  
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Lastly, this project was limited by data collection from a single institution.  Collaboration was 
attempted with outside institutions, but we found the completeness of outside data sets (i.e. not 
differentiating rete testis invasion from pagetoid spread or lack of hilar soft tissue invasion data) to 
be a recurring problem.  Additionally, grossing protocols differed between institutions, and we found 
sampling of both hilar regions and spermatic cord to be drastically different over time and in 
different locations.  By adhering to a single institution, we were able to adequately review the slides 
from all cases included and access clinical data necessary to confirm the clinical stage.  
The results of this study underscore the importance of tumor size and lymphovascular 
invasion in the risk stratification of pure testicular seminomas.  While tumor size has recently been 
added to the AJCC staging system for testicular germ cell tumors, the cutoff provided is 3 cm, which 
is not supported by our current study.  Additionally, tumor size is only used to subclassify pathologic 
staging of pT1 into pT1a and pT1b.  Without other evidence of advanced disease, these cases will 
both be considered clinical stage IA, and therefore, at very low risk for recurrence.  We have 
identified tumor size >/= to 4 cm as a risk factor for metastases, and, as such, given equal weight as 
lymphovascular invasion in pathologic staging.  Consequently, our study supports adding tumor size 
of >/= 4 cm to future staging systems as pT2 in cases of pure seminomas, and we call for continued 
study to further validate this at other institutions or in larger data sets.  Other large cohort studies 
have also demonstrated the importance of tumor size in seminomas, leaving this factor as the lone 
histologic criteria that has been well supported by outside studies in seminomas in particular.4,7,9 In 
addition to this outside support, the AJCC system notes that there is minimal support for a specific 
size cutoff in the current literature.11 While Chung et al. and Nayan et al. both showed significant 
increase in relapse using a cutoff of 3 cm, both Warde et al.’s study and Groll, Warde, and Jewett’s 
comprehensive review support the use of a 4 cm tumor size cutoff and our study adds support to 
this value.4,9,14,15  
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In conclusion, vascular invasion and tumor size >/= 4 cm are strong independent predictors 
of metastases in cases of pure testicular seminomas with a fair predictive model using these two 
criteria alone (AUC=0.7, figure 3).  Extratesticular extension in the hilum was not found to be a 
significant risk factor for metastases as has been shown for nonseminomatous germ cell tumors, 
likely due to the low rate of cases that present at this advanced stage in comparison to 
nonseminomatous germ cell tumors and the great deal of overlap between hilar soft tissue and rete 
testis invasion, making independence difficult to support by multivariate analysis.  
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Figure Legend:  
Figure 1. Invasion of rete testis by seminoma, 1A; Gross morphology of seminoma extending into 
hilar structures, 1B; Stromal invasion of rete testis by seminoma (arrows showing rete testis 
tubules), 1C; Rete testis pagetoid extension of seminoma (arrows indicating seminoma cells) , 1D; 
Invasion of hilar soft tissue by seminoma. 
Figure 2. ROC curve for the prediction of advanced clinical stage based on logistic regression model 
 
Tables: 
Table 1.  Comparison of clinical and histologic variables between clinical stage I and advanced clinical 
stage patients. 
Table 2.  Multivariate logistical regression of risk factors for metastatic disease. 
Table 3.  Analysis of various tumor size cutoff values and the relationship to metastatic disease. 
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Table 1.  Comparison of clinical and histologic variables between clinical stage I and 
advanced clinical stage patients. 
 
Variables  
Total 
(N = 170) 
Clinical 
Stage I  
(N = 138) 
Clinical 
Stage II or III 
(N = 32) 
P Value 
Age, mean (sd) 37.4 (9.5) 36.7 (9.1) 39.9 (10.8) 0.087 
Tumor size, mean (sd) 4.2 (2.3) 3.9 (2.1) 5.4 (2.7) 0.006 
Vascular invasion       0.01 
No 145 (85.3%) 123 (89.1%) 22 (68.8%)   
Yes 25 (14.7%) 15 (10.9%) 10 (31.3%)   
Rete testis invasion       0.11 
Unknown 15 15     
No 65 (41.9%) 56 (45.5%) 9 (28.1%)   
Yes 90 (58.1%) 67 (54.5%) 23 (71.9%)   
Rete pagetoid spread       0.068 
Unknown 25 22 3   
No 117 (80.7%) 90 (77.6%) 27 (93.1%)   
Yes 28 (19.3%) 26 (22.4%) 2 (6.9%)   
Tunica vaginalis invasion       0.16 
No 166 (97.6%) 136 (98.6%) 30 (93.8%)   
Yes 4 (2.4%) 2 (1.4%) 2 (6.3%)   
Tunica albuginea invasion       0.51 
Unknown 22 19 3   
No 100 (67.6%) 82 (68.9%) 18 (62.1%)   
Yes 48 (32.4%) 37 (31.1%) 11 (37.9%)   
Hilar soft tissue invasion       0.05 
Unknown 12 11 1   
No 124 (78.5%) 104 (81.9%) 20 (64.5%)   
Yes 34 (21.5%) 23 (18.1%) 11 (35.5%)   
Epididymal invasion       0.012 
Unknown 8 6 2   
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No 153 (94.4%) 128 (97.0%) 25 (83.3%)   
Yes 9 (5.6%) 4 (3.0%) 5 (16.7%)   
Epididymal pagetoid extension        1 
Unknown 10 7 3   
No 159 (99.4%) 130 (99.2%) 29 (100%)   
Yes 1 (0.6%) 1 (0.8%) 0 (0%)   
Spermatic cord invasion       0.047 
No 165 (97.1%) 136 (98.6%) 29 (90.6%)   
Yes 5 (2.9%) 2 (1.4%) 3 (9.4%)   
 
 
 
Table 2.  Multivariate logistical regression of risk factors for metastatic disease. 
 
 
  
Odds Ratio (95% 
Confidence interval) 
P- Value 
Tumor size 1.27 (1.06 - 1.5) 0.008 
Vascular invasion 2.83 (1.09 - 7.32) 0.032 
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Table 3.  Analysis of various tumor size cutoff values and the relationship to 
metastatic disease. 
 
 
Tumor 
size 
Clinical stage I 
(N=138) 
Clinical stage II 
and III (N=32) 
p-value Odds 
ratio 
Confidence 
Interval 
(95%) 
<2 cm 22 5 0.965 1.02 0.36-2.95 
>/= 2 cm 116 27    
<3 cm 49 8 0.257 1.65 0.73-3.73 
>/= 3 cm 89 24    
<4 cm 80 9 0.002 3.52 1.63-7.61 
>/= 4 cm 58 23    
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